The Resilience Paradox: Chronic Metabolic Adaptation as a Predictor of Delayed Iatrogenic Collapse in Geriatric Oncology

Background: Geriatric oncology faces a paradox: some elderly 
patients with significant comorbidity exhibit unexpectedly high 
tolerance to aggressive anticancer therapies, yet later experience 
severe or fatal complications from minor medical interventions. 
The Hypothesis: We propose that chronic, low-grade intoxication 
(e.g., from ethanol) induces a state of systemic pathological cross
tolerance. This state is mediated by persistent upregulation of 
detoxification systems (CYP2E1, ALDH, GST), stress-response 
pathways, and anti-apoptotic programs. While clinically 
manifesting as reduced acute toxicity, this adaptation 
1 
progressively depletes reparative and homeostatic reserves. 
Upon completion of oncologic treatment, subsequent routine 
stressors (surgery, infection, new drugs) can trigger a 
disproportionate systemic failure due to this exhausted adaptive 
capacity. 
Implications of the Hypothesis: Counterintuitively, apparent 
"excellent tolerance" to toxic therapy could serve as a biomarker 
of high long-term iatrogenic risk. Identifying patients with this 
metabolic-adaptation phenotype (e.g., via CYP2E1 activity or 
oxidative stress markers) and implementing "reserve
preservation" clinical algorithms could reduce delayed non
cancer mortality in elderly survivors.